Executive takeaway for procurement and process chemists: 6-Chloropyridazin-3-amine is a deceptively simple pyridazine building block whose commercial relevance hinges almost entirely on its role as the penultimate intermediate to 6-chloroimidazo[1,2-b]pyridazine — a scaffold embedded in cephalosporin-class antibacterial side chains and urea herbicides. For buyers, the practical selection axis is not whether 97% material will work, but whether the 2–3% impurity profile introduces downstream cyclocondensation failures that erase the cost advantage of the lower grade.
Product Selection: What the Purity Tiers Actually Mean
Commercial listings for CAS 5469-69-2 cluster around three grades — 97%, 98%, and 99% — with the bulk of catalog and bulk inventory sitting at ≥98%. The specification gap is narrower than it appears on paper: a 97% lot may pass GC purity but carry residual 3,6-dichloropyridazine from incomplete amination, a bifunctional impurity that can cross-react in subsequent steps. For teams running the amination of 3,6-dichloropyridazine with aqueous ammonia, the crude isolate is typically a crystalline solid collected by filtration and water wash; the efficiency of that wash step is what separates a clean 98% lot from a marginal 97% one.
Selection guidance by end-use:
| Downstream application | Recommended grade | Rationale |
|---|---|---|
| Medicinal chemistry building block / fragment elaboration | ≥98%, small pack | Reproducibility matters more than unit cost at gram scale |
| Process-scale imidazo[1,2-b]pyridazine synthesis | ≥99% or custom spec on residual dichloropyridazine | Cyclocondensation with chloroacetaldehyde is sensitive to competing amine sites |
| Herbicide intermediate (urea class) | 97–98% acceptable, pending impurity ID | Cost-driven; confirm dichloropyridazine limit with supplier CoA |
The global supplier landscape is fragmented: Thermo Fisher, TCI, BLD Pharmatech, Biosynth Carbosynth, Oakwood, and a cluster of China-based producers (Rosewa, Win-Win Chemical, Hairui) all list the compound, with no single player holding dominant share. That fragmentation cuts both ways — competitive pricing on standard grades, but inconsistent impurity profiles across vendors. Requesting a representative lot CoA with residual dichloropyridazine reported, not just GC area percent, is the single highest-leverage sourcing action.
Price Snapshot: The Spread Is Real
Recent listing data from ChemicalBook shows the spread between research-grade and bulk-grade material is substantial. At the low end, 100 g packs from China-based suppliers sit around ¥180, scaling to ¥1,100 for 1 kg; TCI’s >98% material lists at ¥180 for 25 g; Thermo Scientific’s 97% grade reaches ¥2,516 for 50 g. The message for sourcing managers is straightforward: brand premium buys documentation and lot traceability, not necessarily a chemically superior molecule at this stage of the supply chain. For pilot-scale work where the intermediate will be consumed within one or two synthetic steps, qualifying a lower-cost vendor against an in-house impurity method is likely to yield more savings than negotiating on the catalog price of a Tier 1 brand.
Industry Hot Spot: Why This Small Molecule Keeps Appearing in Market Reports
Two separate market research publishers have issued 2026-dated reports on 3-amino-6-chloropyridazine, both framing the compound as a “important chemical intermediate” with “sustained stable growth” driven by pharmaceutical and agrochemical demand. The reports are paywalled and the headline figures are redacted in the public summaries — a familiar pattern in fine-chemical market intelligence. What is verifiable is the structural driver: 6-chloroimidazo[1,2-b]pyridazine, the direct downstream, is explicitly identified in patent literature as a raw material for cephalosporin antibacterial agents and urea herbicides. Cephalosporin API demand is not a high-growth story, but it is a durable one, and the herbicide channel adds a cyclical buffer.
The more interesting technical signal is in process chemistry. A Japanese patent filing (JP2007091723A) addresses the central inefficiency in the standard route — amination of 3,6-dichloropyridazine with ammonia — by running the reaction in the presence of a water-soluble polyether (diethylene glycol dimethyl ether or triethylene glycol dimethyl ether) to improve yield. The patent explicitly states that conventional concentrated aqueous ammonia and ammonia/ethanol methods were “not industrially satisfactory” in yield. For buyers who also manufacture downstream, this is a reminder that the cost of this intermediate is not fixed by raw material alone; it is sensitive to process IP that may or may not be licensed into the supply base.
Safety and Handling: The Compliance Box
6-Chloropyridazin-3-amine carries GHS classifications H302 (harmful if swallowed, ~81% of notifiers), H315 (skin irritation, 100%), H319 (eye irritation, 100%), and H335 (respiratory irritation, ~98%). It is listed on the TSCA Inventory as active. Storage recommendations from suppliers include −20°C for powder (long-term) and ambient shipping. None of this is unusual for an aniline-like heteroaromatic amine, but procurement should confirm that China-origin material comes with a current SDS in the destination language and that the supplier’s H-code classification matches the ECHA aggregated notifications rather than a generic template.
Bottom line: This is a mature, multi-source intermediate with a clear downstream anchor and no supply-chain fragility. The sourcing decision is less about finding the molecule and more about qualifying the impurity window that matches your downstream chemistry.
